Uniqsis expands LED photoreactor range
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.
Uniqsis announces its PhotoSyn high-power photoreactor light module for continuous flow chemistry is now available with alternative LED array configurations that makes it compatible with a broader range of photochemical reactions.
The availability of three new alternative switchable LED configurations (blue, UVA-blue and blue-green-white) provides chemists with the unique ability to optimally undertake almost any photochemistry reaction. The operating wavelengths of the three LED array configurations are blue (455 nm), blue-green-white (455 nm, 530 nm and 420-700 nm) and UVA-blue (365 nm and 455 nm).
The curved, water-cooled LED arrays in the PhotoSyn are designed to maximise photon intensity and concentrate the available light on the independently temperature controlled central coil reactor. These high-quality LED’s have lifetimes of several years in continuous use without suffering a significant reduction in intensities.
The PhotoSyn incorporates a cooling fan to minimise undesirable radiative heating of the flow reactor whilst being cleverly engineered to completely prevent potentially hazardous light emissions from the unit, thereby avoiding the need to operate the instrument in a shielded enclosure. Moreover, the PhotoSyn is protected with safety interlocks that deactivate the light source and protect the user if any attempt is made to remove the cover whilst in use.
The PhotoSyn is compatible with both the Uniqsis Cold Coil standalone reactor module and the Polar Bear Plus Flow cryogenic flow reactor, which control the coil reactor temperature independently of the lamps. Reactions may be run from 150 °C down to sub-ambient temperatures dependent upon the power of the cooling unit used. The variable power supply allows the lamp power output to be adjusted from 10-100% making the unit suitable for both small scale R&D and scale up applications.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance